11 stories mentioning ASX:RMDUpdated 17d ago
Every FINWIRES story that references ASX:RMD, newest first.
ResMed (ASX:RMD) has an average rating of overweight and mean price target of AU$38.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
ResMed (ASX:RMD) has an average rating of overweight and mean price target of AU$39, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
ResMed's (ASX:RMD) deal to sell its MatrixCare and HealthCare First businesses is "a good example" of the company's willingness to recycle capital from rationalizing underperforming units, Jarden said in a Wednesday note.The company built its out-of-hospital software portfolio through various strategic acquisitions, but its residential care software division has seen softer growth in recent quarters due to low growth and margins, the equity research firm said.The sale of the businesses to Frazier Healthcare Partners carries a price tag of $490 million, which is well below the $876 million ResMed paid for both MatrixCare and HealthCare First, "pointing to a large loss on sale that is yet to be quantified" by the company, Jarden said.Meanwhile, ResMed will implement an enhanced and accretive buyback, and Jarden expects further upside to earnings per share from a potential increase to the repurchase program.Following the sale of MatrixCare and HealthCare First, ResMed anticipates its remaining software as a service portfolio reaccelerating back to high single-digit top-line growth.Jarden maintained an overweight rating on ResMed while reducing its price target to AU$40.20 from AU$42.70.ResMed shares fell 3% in recent Thursday trade.
Australian shares declined on Wednesday as investors reacted to a surge in oil prices on the back of renewed hostilities between the US and Iran in the Middle East.The S&P/ASX 200 Index fell by 0.21%, or 18.80 points, to close at 8,785.10.Brent crude oil futures rose over 3% to trade around $76 per barrel as the US attacked targets in Iran after Iran targeted shipping in the Strait of Hormuz. The US also moved to withdraw a sanctions waiver allowing Iran to sell oil on the global market, which Iran said breached the memorandum of understanding to end the conflict.On the domestic front, the seasonally adjusted estimate for the number of dwellings approved in Australia fell 1.1% month-over-month in May to 17,019 after edging 0.2% lower in April, the Australian Bureau of Statistics said.The number of dwellings commenced in Australia fell 11.2% to 48,012 in the March quarter from the previous quarter, but rose 0.2% from the same period a year earlier.In company news, ResMed (ASX:RMD) agreed to sell its MatrixCare business to healthcare-focused private equity firm Frazier Healthcare Partners in a $490 million all-cash deal.The US Forest Service has issued the final record of decision for South32 (ASX:S32) unit South32 Hermosa's proposed $2.16 billion Hermosa critical mineral project in Arizona's Santa Cruz County, marking a major regulatory milestone for the planned mining and processing operation.Lastly, Adairs (ASX:ADH) expects fiscal year 2026 group underlying earnings before interest and tax (EBIT) in the range of AU$53.5 million to AU$55.5 million, down 1.3% at the midpoint from fiscal year 2025. The company said it expects to recognize a non-cash impairment of the Focus on Furniture goodwill and brand intangible in the range of AU$62 million to AU$68 million to be excluded from underlying earnings.
ResMed (ASX:RMD) completed its acquisition of Noctrix Health, a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders, according to a Tuesday statement by the company.The acquisition broadens the company's clinical sleep health portfolio into an adjacent area with significant unmet need, focusing on the treatment of restless legs syndrome, the third most prevalent sleep disorder.The deal includes Noctrix's US Food and Drug Administration de novo-cleared Nidra tonic motor activation therapy, a clinically validated treatment that reduces restless leg syndrome symptoms and improves sleep quality in patients unresponsive to drug therapies.The company said the acquisition supports its 2030 strategy to scale connected home sleep and health solutions.
ResMed (ASX:RMD) shares were up almost 2% in recent Wednesday trade after the company said late Tuesday it has partnered with smart ring maker Oura to expand access to sleep health education and pathways to care.The company said in a statement that insights from wearable devices, including the Oura Ring, can help people better understand their sleep patterns and encourage informed conversations with healthcare providers about potential sleep disorders, including obstructive sleep apnea.Oura members who experience a higher number of nighttime breathing disturbances can connect to ResMed resources, including educational materials, a sleep assessment, the option to connect with an independent healthcare provider virtually or in-person, and an informative guide to support discussions with their healthcare provider, the company said.The experience is available to users of Oura Ring Gen3 and Oura Ring 4 with an active Oura Membership in the US, it added.
CSL (ASX:CSL) led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed (ASX:RMD) and Cochlear (ASX:COH) followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
(Updates to add stock movement in the headline and last paragraph)ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.The company's shares fell past 4% in recent Friday trade, earlier hitting their lowest level since February 2024.
Australian shares are poised to rise on Friday as oil prices eased from earlier four-year highs amid volatile trading driven by escalating US-Iran tensions and fears over potential disruptions to Middle East crude supplies.Overnight, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average rose 1%, 0.9%, and 1.6%, respectively.In the macroeconomy, the Australian manufacturing sector returned to modest growth in April, though the improvement masked growing strain from Middle East-driven supply chain disruptions, surging fuel costs, and continued weakness in orders and production, according to a survey by S&P Global.Australia's home value index edged 0.3% higher in April, registering its slowest pace of growth since January 2025 amid declines in Sydney and Melbourne, according to figures from Cotality.Australia's producer price indexes report is due at 11:30 am Sydney time.In corporate news, ANZ Group Holdings (ASX:ANZ) reported Friday fiscal first-half cash earnings of AU$1.242 per share on operating income of AU$11.2 billion, compared with cash earnings of AU$1.17 on operating income of AU$11 billion a year earlier.ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share on revenue of $1.43 billion, compared with earnings of $2.37 on revenue of $1.29 billion a year earlier.Coles Group (ASX:COL) sales revenue for the fiscal third quarter was AU$10.7 billion, up from AU$10.38 billion a year earlier.Australia's benchmark index fell 0.2% or 21.2 points to close at 8,665.80 on Thursday.
ResMed (ASX:RMD) said that Chief Financial Officer Brett Sandercock plans to retire, effective May 4, according to a Friday statement by the company.Aaron Bloomer will succeed Sandercock, who will remain an adviser to the chief executive through 2027, the company said.Bloomer was CFO of Exact Sciences, which was recently acquired by New York Stock Exchange-listed Abbott.
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
